tetano
Editor, Senior Moderator
ACS Chem Neurosci. 2020 Apr 22. doi: 10.1021/acschemneuro.0c00201. [Epub ahead of print]
Neurological Insights of COVID-19 Pandemic.
Das G[SUP]1,[/SUP][SUP]2[/SUP], Mukherjee N[SUP]3[/SUP], Ghosh S[SUP]3,[/SUP][SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis.
KEYWORDS:
COVID-19; SARS-CoV-2; encephalopathy; hACE2; neuroinvasive property; therapeutic intervention
PMID:32320211DOI:10.1021/acschemneuro.0c00201
Neurological Insights of COVID-19 Pandemic.
Das G[SUP]1,[/SUP][SUP]2[/SUP], Mukherjee N[SUP]3[/SUP], Ghosh S[SUP]3,[/SUP][SUP]1,[/SUP][SUP]2[/SUP].
Author information
Abstract
The novel coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has kept the whole world in tenterhooks due to its severe life-threatening nature of the infection. The virus is unlike its previous counterparts, SARS-CoV and MERS-CoV, or anything the world has encountered before both in terms of virulence and severity of the infection. If scientific reports relevant to the SARS-CoV-2 virus are noted, it can be seen that the virus owes much of its killer properties to its unique structure that has a stronger binding affinity with the human angiotensin-converting enzyme 2 (hACE2) protein, which the viruses utilize as an entry point to gain accesses to its hosts. Recent reports suggest that it is not just the lung that the virus may be targeting; the human brain may soon emerge as the new abode of the virus. Already instances of patients with COVID-19 have been reported with mild (anosmia and ageusia) to severe (encephalopathy) neurological manifestations, and if that is so, then it gives us more reasons to be frightened of this killer virus. Keeping in mind that the situation does not worsen from here, immediate awareness and more thorough research regarding the neuroinvasive nature of the virus is the immediate need of the hour. Scientists globally also need to up their game to design more specific therapeutic strategies with the available information to counteract the pandemic. In this Viewpoint, we provide a brief outline of the currently known neurological manifestations of COVID-19 and discuss some probable ways to design therapeutic strategies to overcome the present global crisis.
KEYWORDS:
COVID-19; SARS-CoV-2; encephalopathy; hACE2; neuroinvasive property; therapeutic intervention
PMID:32320211DOI:10.1021/acschemneuro.0c00201